Arcturus Therapeutics Holdings (ARCT) EBITDA Margin (2018 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly EBITDA Margin came in at 1403.74% in Q1 2026, down 134647.0% YoY from N/an in Q1 2025, and down 222.65% on a QoQ basis from 435.06% in Q4 2025.
Powered by 
Analysis
Arcturus Therapeutics Holdings (ARCT) EBITDA Margin (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 9 years of EBITDA Margin data on file, last reported at 1403.74% in Q1 2026.
- Quarterly EBITDA Margin fell 134647.0% year-over-year to 1403.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 161.52% (down 10439.0% YoY) and the FY2025 annual result came in at 92.96%, down 3015.0% from the prior year.
- EBITDA Margin retreated to 1403.74% in Q1 2026, from 435.06% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 75.77% in Q4 2022 to a low of 1403.74% in Q1 2026.
- A 5-year average of 245.88% and a median of 80.01% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin surged 260313 bps — and 2026, when it tumbled 134647 bps.
- Tracing ARCT's EBITDA Margin over 5 years: stood at 75.77% in 2022, then sank by 178 bps to 59.22% in 2023, then tumbled by 148 bps to 146.68% in 2024, then slumped by 197 bps to 435.06% in 2025, then sank by 223 bps to 1403.74% in 2026.
- The last three EBITDA Margin figures came in at 1403.74% (Q1 2026), 435.06% (Q4 2025), and 96.27% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Arcturus Therapeutics Holdings | 449.65 Mn | 258.17 Mn | - | -863.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -863.30% |
| Mar 31, 2026 | -1,403.74% |
| Dec 31, 2025 | -435.06% |
| Sep 30, 2025 | -96.27% |
| Jun 30, 2025 | -41.04% |
| Mar 31, 2025 | -57.27% |
| Dec 31, 2024 | -146.68% |
| Sep 30, 2024 | -25.76% |
| Jun 30, 2024 | -42.37% |
| Mar 31, 2024 | -80.01% |
| Dec 31, 2023 | -59.22% |
| Sep 30, 2023 | -42.79% |
| Jun 30, 2023 | -526.42% |
| Mar 31, 2023 | 18.38% |
| Dec 31, 2022 | 75.77% |
| Sep 30, 2022 | -275.32% |
| Jun 30, 2022 | -81.53% |
| Mar 31, 2022 | -960.70% |
| Dec 31, 2021 | -649.72% |
| Sep 30, 2021 | -2,208.49% |